Results from the efficacy analysis have been submitted to the Vietnam Ministry of Health by Vinbiocare on April 13 and shared with Arcturus in parallel with this filing.
The Phase 3 vaccine efficacy portion of this study enrolled over 16,000 participants. The trial met its primary endpoint of prevention of virologically confirmed COVID-19 disease.
Two 5-mcg doses of ARCT-154 demonstrated 55% vaccine efficacy for protection against COVID-19.
95.3% of vaccine efficacy was observed in severe (including fatal) COVID-19 cases.
Forty-one cases of severe COVID-19 infection occurred in the placebo group, and two in the ARCT-154 vaccinated group.
Nine COVID-19-related deaths were reported in the placebo group and 1 in the ARCT-154 older age group participant who was also at increased risk of severe COVID-19.
Arcturus has advanced ARCT-154 (5 mcg) toward a pivotal booster study, including approximately 2,400 participants.
Price Action: ARCT shares are down 7.99% at $23.24 during the market session on the last check Wednesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.